Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2024-06-28 DOI:10.1002/hup.2907

Kiumarth Amini, Mohammad-Javad Motallebi, Kimia Bakhtiari, Minoo Sadat Hajmiri, Maryam Zamanirafe, Mahdis Sharifikia, Akram Ranjbar, Amir Keshavarzi, Mahtabalsadat Mirjalili, Maryam Mehrpooya

{"title":"Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia","authors":"Kiumarth Amini, Mohammad-Javad Motallebi, Kimia Bakhtiari, Minoo Sadat Hajmiri, Maryam Zamanirafe, Mahdis Sharifikia, Akram Ranjbar, Amir Keshavarzi, Mahtabalsadat Mirjalili, Maryam Mehrpooya","doi":"10.1002/hup.2907","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In this cross-sectional study, we compared fasting serum asprosin levels and metabolic parameters between patients receiving one of three atypical antipsychotics (olanzapine, risperidone, or aripiprazole) and healthy subjects.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study population included 62 adult outpatients with schizophrenia and 22 healthy controls, matched for age and gender. Patients were in remission and had been on stable monotherapy with one of these atypical antipsychotics for over 6 months. Body Mass Index (BMI) and fasting serum levels of asprosin, glucose, HA1c, insulin, and lipid profile were compared across the investigated groups. Additionally, the number of participants meeting the insulin resistance criterion, defined as homeostasis model assessment for insulin resistance (HOMA-IR) >2.5, as well as the number of participants with elevated BMI levels (men >27 kg/m<sup>2</sup>, women >25 kg/m<sup>2</sup>) were compared among the groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We observed statistically significant differences in BMI and fasting serum levels of glucose, HA1c, insulin, triglyceride (TG), high-density lipoprotein cholesterol, and asprosin among patients receiving olanzapine or risperidone, as compared to those receiving aripiprazole and healthy subjects. Patients on aripiprazole exhibited values comparable to healthy subjects, whereas those on risperidone or olanzapine showed significantly higher values, with the highest observed in the olanzapine group. Additionally, the prevalence of participants meeting the insulin resistance criterion and those with elevated BMI was also greater in individuals receiving olanzapine or risperidone compared to those on aripiprazole and healthy subjects. Serum asprosin levels showed a significant positive correlation with BMI and several metabolic parameters, including HbA1c, fasting insulin, HOMA-IR, and TG. No significant differences were observed among the investigated groups in terms of serum levels of total cholesterol and low-density lipoprotein cholesterol.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our cross-sectional study highlights the association between elevated asprosin levels, weight gain, and metabolic disorders in patients treated with olanzapine and risperidone. Given the bidirectional nature of the relationship between serum asprosin levels and these metabolic disturbances, further research is warranted to elucidate potential causative pathways.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 5","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2907","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

In this cross-sectional study, we compared fasting serum asprosin levels and metabolic parameters between patients receiving one of three atypical antipsychotics (olanzapine, risperidone, or aripiprazole) and healthy subjects.

Methods

The study population included 62 adult outpatients with schizophrenia and 22 healthy controls, matched for age and gender. Patients were in remission and had been on stable monotherapy with one of these atypical antipsychotics for over 6 months. Body Mass Index (BMI) and fasting serum levels of asprosin, glucose, HA1c, insulin, and lipid profile were compared across the investigated groups. Additionally, the number of participants meeting the insulin resistance criterion, defined as homeostasis model assessment for insulin resistance (HOMA-IR) >2.5, as well as the number of participants with elevated BMI levels (men >27 kg/m², women >25 kg/m²) were compared among the groups.

Results

We observed statistically significant differences in BMI and fasting serum levels of glucose, HA1c, insulin, triglyceride (TG), high-density lipoprotein cholesterol, and asprosin among patients receiving olanzapine or risperidone, as compared to those receiving aripiprazole and healthy subjects. Patients on aripiprazole exhibited values comparable to healthy subjects, whereas those on risperidone or olanzapine showed significantly higher values, with the highest observed in the olanzapine group. Additionally, the prevalence of participants meeting the insulin resistance criterion and those with elevated BMI was also greater in individuals receiving olanzapine or risperidone compared to those on aripiprazole and healthy subjects. Serum asprosin levels showed a significant positive correlation with BMI and several metabolic parameters, including HbA1c, fasting insulin, HOMA-IR, and TG. No significant differences were observed among the investigated groups in terms of serum levels of total cholesterol and low-density lipoprotein cholesterol.

Conclusions

Our cross-sectional study highlights the association between elevated asprosin levels, weight gain, and metabolic disorders in patients treated with olanzapine and risperidone. Given the bidirectional nature of the relationship between serum asprosin levels and these metabolic disturbances, further research is warranted to elucidate potential causative pathways.

查看原文本刊更多论文

非典型抗精神病药物对精神分裂症患者血清天冬氨酸水平及其他代谢参数的影响。

研究背景在这项横断面研究中，我们比较了接受三种非典型抗精神病药物（奥氮平、利培酮或阿立哌唑）治疗的患者与健康受试者的空腹血清阿司匹林水平和代谢参数：研究对象包括 62 名成年精神分裂症门诊患者和 22 名健康对照者，年龄和性别均匹配。患者均处于缓解期，并已稳定使用其中一种非典型抗精神病药物超过 6 个月。对各调查组的体重指数（BMI）和空腹血清中的天冬氨酸、葡萄糖、HA1c、胰岛素和血脂水平进行了比较。此外，还比较了各组中符合胰岛素抵抗标准（定义为胰岛素抵抗稳态模型评估（HOMA-IR）>2.5）的人数，以及 BMI 水平升高（男性>27 kg/m2，女性>25 kg/m2）的人数：我们观察到，与阿立哌唑患者和健康受试者相比，接受奥氮平或利培酮治疗的患者在体重指数和空腹血清葡萄糖、HA1c、胰岛素、甘油三酯（TG）、高密度脂蛋白胆固醇和阿司匹林水平方面存在明显的统计学差异。阿立哌唑患者的数值与健康受试者相当，而利培酮或奥氮平患者的数值则明显较高，其中奥氮平组的数值最高。此外，与阿立哌唑和健康受试者相比，服用奥氮平或利培酮的受试者中符合胰岛素抵抗标准和体重指数升高的比例也更高。血清阿司匹林水平与体重指数和几个代谢参数（包括 HbA1c、空腹胰岛素、HOMA-IR 和 TG）呈显著正相关。调查组之间在血清总胆固醇和低密度脂蛋白胆固醇水平方面没有发现明显差异：我们的横断面研究强调了接受奥氮平和利培酮治疗的患者体内阿司匹林水平升高、体重增加和代谢紊乱之间的关联。鉴于血清asprosin水平与这些代谢紊乱之间的关系具有双向性，因此有必要开展进一步研究，以阐明潜在的致病途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design